Table 1.
Estimates of the hepatitis C virus (HCV) chronically infected population (% prevalence and absolute numbers) and the proportion (%) of chronic hepatitis C virus infection (cHCV) attributable to injection drug use in European Union—European Economic Area (EU/EEA) countries.
| Country | Median prevalence (%) of cHCV (95% credible interval) | Population with cHCV (95% credible interval) | Least proportion (%) attributable to injection drug use (95% credible interval) |
|---|---|---|---|
| EU/EEA | 0.50 (0.46, 0.55) | 1,782,923 (1,638,132, 1,941,583) | 35.76 (33.07, 38.60) |
| Eastern Europe | 0.88 (0.81, 0.94) | 634,273 (587,854, 684,696) | 40.34 (37.14, 43.58) |
| Bulgaria | 1.11 (0.83, 1.60) | 62,610 (47,032, 90,766) | 62.56 (43.14, 82.76) |
| Czechia | 0.78 (0.55, 1.11) | 66,794 (46,853, 94,196) | 24.60 (17.22, 35.10) |
| Hungary | 0.23 (0.20, 0.25) | 17,984 (15,962, 20,101) | 48.31 (42.51, 53.36) |
| Poland | 0.36 (0.27, 0.45) | 108,210 (82,261, 137,566) | 4.27 (3.16, 5.83) |
| Romania | 2.26 (2.11, 2.41) | 348,939 (326,554, 372,034) | 46.81 (43.61, 49.97) |
| Slovakia | 0.62 (0.47, 0.78) | 27,407 (20,658, 34,501) | 87.12 (74.69, 95.18) |
| Northern Europe | 0.41 (0.37, 0.45) | 120,493 (109,815, 134,393) | 70.03 (65.03, 73.98) |
| Denmark | 0.27 (0.25, 0.30) | 12,423 (11,262, 13,621) | 97.43 (96.05, 98.45) |
| Estonia | 1.71 (1.49, 2.06) | 17,634 (15,413, 21,306) | 85.48 (71.19, 95.16) |
| Finland | 0.59 (0.53, 0.66) | 25,650 (22,801, 28,477) | 95.91 (94.66, 96.94) |
| Iceland | 0.10 (0.05, 0.20) | 279 (151, 547) | 83 (41.63, 100) |
| Ireland | 0.21 (0.13, 0.35) | 7844 (4,711, 13,035) | 62.31 (37.01, 99.78) |
| Latvia | 0.77 (0.68, 0.87) | 11,640 (10,236, 13,090) | 81.26 (75.43, 87.61) |
| Lithuania | 1.01 (0.94, 1.09) | 22,410 (20,761, 24,139) | 25.05 (22.60, 27.68) |
| Norway | 0.22 (0.14, 0.30) | 9164 (5,954, 12,631) | 76.81 (66.64, 85.48) |
| Sweden | 0.16 (0.07, 0.31) | 12,758 (5,174, 24,732) | 41.89 (33.35, 53.17) |
| Southern Europe | 0.59 (0.50, 0.69) | 633,109 (540,571, 737,905) | 19.38 (16.66, 22.67) |
| Croatia | 0.74 (0.46, 1.11) | 24,274 (15,060, 36,404) | 9.31 (4.92, 17.57) |
| Cyprus | 0.19 (0.15, 0.25) | 1353 (1,035, 1756) | 59.79 (46.03, 73.76) |
| Greece | 0.55 (0.36, 0.80) | 46,260 (30,310, 67,042) | 11.49 (7.75, 17.72) |
| Italy | 0.96 (0.80, 1.15) | 459,000 (379,172, 549,698) | 16.68 (13.87, 20.14) |
| Malta | 0.27 (0.20, 0.35) | 1083 (812, 1398) | 87.56 (76.85, 94.78) |
| Portugal | 0.50 (0.37, 0.78) | 41,161 (30,370, 64,216) | 67.35 (43.13, 90.12) |
| Slovenia | 0.07 (0.02, 0.14) | 1078 (317, 2319) | 83.94 (35.54, 99.35) |
| Spain | 0.15 (0.06, 0.27) | 54,676 (21,352, 101,774) | 15.13 (7.94, 38.84) |
| Western Europe | 0.27 (0.20, 0.34) | 391,737 (297,454, 504,226) | 44.63 (36.45, 53.68) |
| Austria | 0.33 (0.29, 0.38) | 23,860 (20,931, 26,854) | 93.95 (91.72, 95.72) |
| Belgium | 0.18 (0.09, 0.36) | 16,178 (7,737, 31,562) | 20.17 (9.76, 42.62) |
| France | 0.29 (0.16, 0.46) | 142,921 (77,226, 227,201) | 34.28 (20.84, 51.32) |
| Germany | 0.30 (0.21, 0.42) | 196,671 (137,554, 279,639) | 49.29 (37.66, 62.99) |
| Luxembourg | 0.25 (0.15, 0.39) | 1243 (760, 1894) | 73.09 (54.36, 88.46) |
| Netherlands | 0.04 (0, 0.16) | 6183 (0, 21,759) | 26.06 (10.01, 73.86) |
Note: HCV-RNA prevalence is used as a proxy for chronic HCV infection (cHCV); Population: 15–79 years old; Sub-regions names denote the EU/EEA countries within the United Nations sub-regions; Cyprus was grouped into Southern Europe for this analysis.